Trial Profile
Study of the efficacy and safety of escitalopram for the prevention of depressive episodes induced by peg-interferon alpha2a and ribavirin in chronic hepatitis C patients. Randomized, double blind, placebo controlled clinical trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Depression
- Focus Therapeutic Use
- 26 Apr 2009 Results presented at EASL 2009.
- 07 Mar 2008 New trial record.